Delivery Order SPE2DB25D3402-SPE2DB25FUGJR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- The Defense Logistics Agency awarded a $31,088.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of 36,000 units of Creon DR 100s capsules. The contract, which is not set-aside, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. Performance will be completed by August 20, 2025, with fulfillment...
- The Defense Logistics Agency awarded a $1,725.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $45,421.87 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s. This contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was competitively procured and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Creon is a pancreatic enzyme replacement...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 units of Creon DR 100s capsules valued at $7,245.28. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award through open competition. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,198.70 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Creon is a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency, reflecting DLA's role in supplying...
- The Defense Logistics Agency awarded a delivery order valued at $42,783.63 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of 36,000 units of Creon DR 100s capsules. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,117.97 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon DR 100s. This competitively awarded contract, which carries no set-aside designation, was executed on August 13, 2025, with an ultimate completion date of August 14, 2025. The firm fixed price delivery order will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with a contract value of $9,718.75. The order was competitively awarded without set-aside designation and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates under a firm...
- SPE2DB25D3402Indefinite Delivery Contract
- SPE2DB25D3402-SPE2DB25FUGJRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,004.53 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 capsules, with an ultimate completion date of July 30, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, awarded competitively on July 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Creon DR is an enzyme replacement therapy used to treat pancreatic insufficiency, indicating this delivery supports pharmaceutical supply needs within the federal healthcare system. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally, enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs and other federal medical systems. The company's extensive federal contract portfolio demonstrates its critical role as a pharmaceutical distributor serving the Defense Health Agency and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/29/25 |